Gelonghui June 29?Fine Pharmaceutical (00858.HK) announced that for the year ended March 31, 2023, the company's income was HK $72.577 million, down 1.82% from the same period last year; the company's profit for the period attributable to shareholders was HK $129 million, down 1.01% from the same period last year; and basic earnings per share was HK5.41 cents.
Although earnings remained relatively stable, gross profit decreased, which was due to the mandatory factory blockade imposed by the government in Changchun City (including the group's local production plant) between March and May 2022, resulting in a decline in production. in addition, the disruption of the supply chain caused by transport logistics and travel restrictions has led to an increase in the cost of sales, as well as the short-term impact caused by the disruption and some changes in the sales mix. Reduce the gross margin from 50.8% to 42.9%.